Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.56 |
| ▸ | ESRRB | O95718 | 1/20 | 0.55 |
| ▸ | ESRRG | P62508 | 1/20 | 0.55 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5176812 | 0.87 | P2RX7 (0.57) | EPHX2NR1H4ESRRBESRRG | |
| SCHEMBL4027739 | 0.85 | ESRRG (0.74) | EPHX2NR1H4ESRRBESRRG | |
| SCHEMBL3271866 | 0.85 | KMT2A (0.68) | ALDH1A1EPHX2NR1H4ESRRBESRRG | |
| SCHEMBL3278159 | 0.85 | LMNA (0.68) | ALDH1A1GAAMAPTEPHX2NR1H4 | |
| SCHEMBL3942498 | 0.84 | MEN1 (0.71) | ALDH1A1EPHX2NR1H4ESRRBESRRG | |
| SCHEMBL3273904 | 0.84 | LMNA (0.70) | ALDH1A1GAAEPHX2NR1H4ESRRB | |
| SCHEMBL5177433 | 0.83 | ALDH1A1 (0.68) | ALDH1A1GAAMAPTRAB9A | |
| Hydrochloric Acid SCHEMBL4026084 | 0.82 | LMNA (0.68) | ALDH1A1GAAEPHX2NR1H4ESRRB | |
| SCHEMBL7848467 | 0.82 | EPHX2 (0.70) | ALDH1A1MAPTEPHX2NR1H4RAB9A | |
| SCHEMBL12042426 | 0.82 | LMNA (0.72) | ALDH1A1MAPTEPHX2NR1H4RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7259183-B2 | Indole, indazole and indoline derivatives as CETP inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2007-08-21 | — | — | US | disclosed |
| EP-1776338-A1 | INDOLE, INDAZOLE OR INDOLINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-04-25 | — | — | EP | disclosed |
| US-20060030613-A1 | Indole, indazole and indoline derivatives as CETP inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | US | disclosed |
| WO-2006013048-A1 | INDOLE, INDAZOLE OR INDOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030613-A1 | Indole, indazole and indoline derivatives as CETP inhibitors | CETP, NAT1, MTTP | ALDH1A1 2428/4885GAA 1577/4885MAPT 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.